Pacira BioSciences (PCRX) Amortizatization of Intangibles (2010 - 2026)
Pacira BioSciences' (PCRX) quarterly Amortizatization of Intangibles came in at $570000.0 in Q1 2026, down 70.16% year-on-year from $1.9 million in Q1 2025, and down 88.19% quarter-over-quarter from $4.8 million in Q4 2025.
Pacira BioSciences (PCRX) Amortizatization of Intangibles (2010 - 2026) Analysis & Trends
Pacira BioSciences' Amortizatization of Intangibles history runs 17 years deep, the most recent figure standing at $570000.0 for Q1 2026.
- On a quarterly basis, Amortizatization of Intangibles fell 70.16% year-over-year to $570000.0 in Q1 2026; TTM through Mar 2026 was $5.5 million, a 41.17% decrease from a year earlier, with the FY2025 full-year figure at $4.9 million, down 33.61% from the prior year.
- Amortizatization of Intangibles declined to $570000.0 in Q1 2026 per PCRX's latest filing, from $4.8 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $7.4 million in Q4 2024 and bottomed at $23000.0 in Q2 2024.
- The 5-year median for Amortizatization of Intangibles is $675000.0 (2023), against an average of $1.3 million.
- Across the five-year window, Amortizatization of Intangibles slumped 96.44% in 2024 and soared 7858.33% in 2025, its largest moves.
- Year by year, Amortizatization of Intangibles stood at $700000.0 in 2022, then surged by 449.71% to $3.8 million in 2023, then surged by 91.03% to $7.4 million in 2024, then tumbled by 34.35% to $4.8 million in 2025, then slumped by 88.19% to $570000.0 in 2026.
- Per Business Quant, the three latest PCRX Amortizatization of Intangibles figures stand at $570000.0 (Q1 2026), $4.8 million (Q4 2025), and $56000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Pacira BioSciences | 1.08 Bn | 876.91 Mn | 140.96 Mn | 570,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 570,000.00 |
| Mar 31, 2026 | 570,000.00 |
| Dec 31, 2025 | 4.83 Mn |
| Dec 31, 2025 | 4.83 Mn |
| Sep 30, 2025 | 56,000.00 |
| Sep 30, 2025 | 56,000.00 |
| Jun 30, 2025 | 23,000.00 |
| Jun 30, 2025 | 23,000.00 |
| Mar 31, 2025 | 1.91 Mn |
| Mar 31, 2025 | 1.91 Mn |
| Dec 31, 2024 | 7.35 Mn |
| Dec 31, 2024 | 7.35 Mn |
| Sep 30, 2024 | 23,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Jun 30, 2024 | 23,000.00 |
| Jun 30, 2024 | 23,000.00 |
| Mar 31, 2024 | 24,000.00 |
| Mar 31, 2024 | 24,000.00 |
| Dec 31, 2023 | 3.85 Mn |
| Dec 31, 2023 | 3.85 Mn |